Observational studyBMC musculoskeletal disorders2025
Sequential anti-osteoporotic therapy with teriparatide and alendronate optimizes outcomes of percutaneous vertebroplasty in acute osteoporotic vertebral fractures: a 12-month prospective cohort study.
Observational study in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03692143 (Effect and Cost Comparation of Different Treatment Strategies for Osteoporotic Vertebral Fractures), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect and Cost Comparation of Different Treatment Strategies for Osteoporotic Vertebral Fractures (OVF): Teriparatide Injection and Percutaneous Vertebroplasty (PVP)
Who cites it
1 citing paper in PubMed.
- Osteoporosis: The Renascent Impact of Vertebral Fractures-A Narrative Review of Diagnosis, Risk Stratification, and Integrated Management.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPercutaneous vertebroplasty (PVP) is widely utilized for managing osteoporotic vertebral compression fractures (OVCFs), yet its long-term efficacy remains controversial. Previous studies have overlooked the potential impact of anti-osteoporotic medications on PVP outcomes. This study evaluates the clinical benefits of PVP combined with alendronate (ALN) or sequential teriparatide (TPTD)/ALN therapy in postmenopausal women with acute OVCFs.
methodIn this prospective cohort study, 216 postmenopausal women with fresh OVCFs were allocated to four groups based on patients' preference: ALN monotherapy (ALN group), PVP combined with ALN therapy (ALN + PVP group), sequential therapy with TPTD for 6 months followed by ALN (TPTD group), and PVP combined with sequential TPTD/ALN therapy (TPTD + PVP group). Pain (Visual Analog Scale, VAS), disability (Oswestry Disability Index, ODI), and health-related quality of life (Medical Outcomes Study 36-Item Short Form Health Survey, SF-36) were assessed at 3, 6, and 12 months by one-way ANOVA. New vertebral fracture incidence was monitored biannually.
resultsCompared to ALN group, the ALN + PVP, TPTD and TPTD + PVP groups exhibited significantly improved VAS scores at 3, 6 and 12 months (p < 0.05), as well as superior SF-36 scores at 3 and 6 months (p < 0.05). No significant differences in VAS, ODI or SF-36 scores were observed among ALN + PVP, TPTD and TPTD + PVP groups during follow-up (p > 0.05), except TPTD + PVP group exhibited a statistically superior improvement than ALN + PVP group in SF-36 scores at 12 months. New vertebral fracture incidences at 30 months were 10.0% (ALN), 19.0% (ALN + PVP), 5.4% (TPTD) and 14.3% (TPTD + PVP).
conclusionsThe application of anti-osteoporotic medicine could affect the beneficial effect evaluation of PVP. Sequential TPTD/ALN therapy achieved comparable pain relief and health-related quality of life improvements to PVP combined with anti-osteoporotic agents, while demonstrating the lowest long-term refracture rate. These findings suggest that conservative sequential TPTD/ALN therapy may serve as an effective alternative to PVP in acute OVCFs management. Larger randomized trials are warranted to validate these results. CLINICAL TRIAL REGISTRATION NUMBER: NCT03692143.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.